| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
From the University of Southern California Neuromuscular Center, Department of Neurology, University of Southern California Keck School of Medicine, Good Samaritan Hospital, Los Angeles, California
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
In AD neurons, active extracellular signal-regulated protein kinase (ERK) has been immunocolocalized with both phosphorylated tau8,9 and 8-hydroxyguanosine,9 a marker of oxidative damage. Accordingly, ERK was proposed to link oxidative stress to the AD brain pathology.9 In our exploration of the pathogenic cascade leading to IBM, including mechanisms of tau phosphorylation, and the possible influence of oxidative stress, we studied the expression of the active, phosphorylated ERK in IBM muscle biopsies. ERK is a serine/threonine protein kinase that was shown in cell culture to be activated by reactive oxygen species.10,11 In vitro, ERK phosphorylates the same residues of tau that are phosphorylated in AD neurofibrillary tangles.12,13
| Materials and Methods |
|---|
|
|
|---|
Immunocytochemical studies were performed on sections of diagnostic muscle biopsies obtained from 20 patients with these diagnoses: IBM (n = 6), dermatomyositis (n = 2), polymyositis (n = 2), morphologically nonspecific myopathy (n = 2), amyotrophic lateral sclerosis (n = 3), chronic peripheral neuropathy (n = 1), non-IBM vacuolar myopathy (n = 1), and normal muscle (n = 3). Diagnoses were based on clinical and laboratory investigations, including 18-reaction histochemistry of the muscle biopsy.
Light Microscopy Immunocytochemistry
Immunocytochemistry was performed on 10-µm-thick sections of the
fresh-frozen biopsies. The sections were either unfixed or prefixed
with acetone or 2% paraformaldehyde. Peroxidase-antiperoxidase and
immunofluorescence procedures were performed as
described.2-4,6
To localize active ERK we used two rabbit
polyclonal antibodies (New England Biolabs, Beverly, MA; and Promega,
Madison, WI), diluted 1:20 to 1:100. Both antibodies specifically
recognize dually phosphorylated epitopes, p-Ser202/p-Tyr204 and
p-Ser183/p-Tyr185, on ERK1 and ERK2, respectively (8, 9 and
immunoblots provided by the companies). Double-immunofluorescence used
rabbit polyclonal antibody against ERK combined with: 1) mouse
monoclonal antibody AT8 (Innogenetics, Alharetto, GA), a
well-characterized specific marker of PHF tau in both AD and IBM that
recognizes dually phosphorylated Ser202/Thr205 epitope (according to
the sequence of the longest human tau isoform);3,14
2) a
mouse monoclonal antibody against desmin (Chemicon International, Inc.,
Temecula, CA), which identifies regenerating (positive) and necrotic
(negative) muscle fibers; 3)
-bungarotoxin (
-BT) conjugated to
fluorescent marker Alexa (Molecular Probes, Eugene, OR), which
binds to the postsynaptic nicotinic acetylcholine receptors at
neuromuscular junctions (NMJs); 4) a mouse monoclonal antibody against
CD163 (clone Ber-MAC3; DAKO, Carpinteria, CA), thereby recognizing
human macrophages; or 5) Hoechst 33342 (Molecular Probes), a
DNA-binding dye illuminating nuclei.
To block nonspecific binding of antibody to Fc receptors, the sections were preincubated with normal goat serum diluted 1:10. Omission of the primary antibody or its replacement with nonimmune serum or irrelevant antibodies were used to control for specificity, as described.2-4,6
Immunoelectronmicroscopy
This was performed on 10-µm, unfixed frozen sections adhered to the bottom of 35-mm Petri dishes.2-4,6 Active ERK was immunolocalized with a HRP-conjugated secondary antibody, or was doubly-immunolocalized with monoclonal SMI-31 antibody (Sternberger Monoclonals, Baltimore, MD), using two appropriate secondary antibodies conjugated either to 10-nm or 5-nm gold particles.2-4,6 SMI-31 antibody cross-reacts with PHF- phosphorylated tau of both IBM muscle3 and AD brain,15-17 and it recognizes the dually phosphorylated epitope Ser 396/Ser 404.17
| Results |
|---|
|
|
|---|
IBM
In all IBM biopsies, 80 to 90% of the vacuolated muscle fibers
and 10 to 15% of nonvacuolated ones had strong ERK immunoreactivity
(IR). ERK-IR was in the form of numerous, well-defined squiggly,
linear, or dotty inclusions (Figure 1, AC
, and Figure 2, A and C
). Occasional
muscle fibers, in addition to the immunoreactive inclusions, had a
slight diffuse cytoplasmic ERK-IR. These patterns of immunostaining
were present in both unfixed and fixed sections. In unfixed or
acetone-fixed sections, ERK-IR in the myonuclei was very weak.
Paraformaldehyde fixation significantly increased ERK-IR of the
myonuclei in all IBM and control biopsies. In IBM, paraformaldehyde
combined with Hoechst counterstaining revealed that only a minority of
the ERK-immunoreactive inclusions in abnormal muscle fibers were
associated with nuclei (Figure 2, FI
, arrows), most being in the
cytoplasm.
|
|
When primary antibody was omitted or replaced with an irrelevant antibody the above-described immunoreactions were not detectable.
Control Muscle Biopsies
None of the control biopsies contained ERK-immunoreactive inclusions characteristic of the IBM abnormal muscle fibers.
At the postsynaptic domain of the neuromuscular junctions in all
control and IBM biopsies that contained them, there was strong ERK-IR.
Depending on the plane of section, ERK-IR either strictly overlapped
with the bound
-BT or occupied a slightly larger territory (Figure 2, JN)
. In all myopathies, macrophages invading necrotic muscle
fibers had increased ERK-IR (Figure 1, D and E)
. Occasionally, weak
diffuse immunoreactivity was present in the cytoplasm of necrotic,
desmin-negative muscle fibers, independently from ERK-immunoreactive
macrophages. The cytoplasm of regenerating fibers was negative, but
after paraformaldehyde fixation slightly increased ERK-IR was
occasionally present in their nuclei.
Immunoelectronmicroscopy
In IBM abnormal muscle fibers, ERK immunolocalized to the clusters
of PHFs. When HRP-labeled secondary antibody was used, the HRP reaction
product labeled PHFs entirely (Figure 3A)
. However, gold immunolabeling
revealed that ERK was very closely associated with the PHFs but its
immunoreactivity was present on very small tufts of amorphous material
adjacent to, and sometimes apparently attached to, the PHFs (Figure 3B
,
arrows). Therefore, it appeared that ERK was not a component of the PHF
backbone itself.
|
| Discussion |
|---|
|
|
|---|
In a various cell types, ERK was shown to be activated by oxidative stress. Reactive oxygen species are thought to activate ERK through modification of the physiological ERK-activation pathways.10 For example, Ras, a physiological ERK inducer, can be activated by nitric oxide through nitrotyrosylation of one of its cysteine residues.20 Although activation of ERK protects various cells in culture from oxidant-mediated death,10 in other cells ERK promotes death induced by reactive oxygen species.11
In the present study, we demonstrated accumulation of active ERK in the IBM abnormal muscle fibers, in activated muscle macrophages, and at the postsynaptic domain of normal human neuromuscular junctions.
The anti-ERK antibodies used in our studies specifically recognize the double-phosphorylated, active form of ERK. In the IBM muscle fibers, at the light-microscopic level ERK-immunoreactive cytoplasmic inclusions were co-labeled with antibodies against phosphorylated tau-containing PHFs. Our immunoelectronmicroscopy with the peroxidase technique demonstrated a high concentration of ERK in the large clusters of PHFs, but the gold technique showed ERK to be in small amorphous tufts among, and often touching, PHFs, but not directly aligned on the PHFs themselves. That appearance suggested that ERK may be associated with formation of nascent PHFs in the tufts, which would be harmonious with the known ability of ERK to phosphorylate tau, which is considered critical to the transformation of tau into PHFs.12,13 The phosphoepitopes of tau phosphorylated by ERK in vitro are the same ones that are recognized by the AT8 and SMI-31 antibodies12,13 used by us to co-localize phosphorylated tau (on PHFs) with ERK, by light microscopy and gold immunoelectronmicroscopy. In some IBM fibers, ERK-IR was either more abundant than that of phosphorylated tau, or there was no detectable tau-IR, suggesting that over-expression of ERK may precede tau phosphorylation. Therefore, our results suggest that in IBM muscle ERK may participate in the pathological phosphorylation of PHF tau. Accordingly, activation of ERK in IBM may be at least one of the underlying causes of PHF formation.
The ERK-immunoreactive inclusions in IBM vacuolated muscle fibers do not reflect macrophages, because our previous study21 using double-labeling with a macrophage-specific marker, and the present study using the macrophage marker anti-CD163, demonstrated that virtually none of the IBM vacuolated muscle fibers contained invading macrophages.
Visualization of the nuclear ERK-IR in this study required paraformaldehyde fixation. Possibly paraformaldehyde protected the active ERK epitope from the degradation by endogenous proteases and/or phosphatases, prevented the extraction of ERK from nuclei, or by cross-linking changed the conformation of active ERK to make it more immunoreactive. Since paraformaldehyde fixation was not required to achieve the very strong staining of IBM-PHFs, ERK associated with the PHFs may be less vulnerable to degradation/extraction, or much more abundant and thus its detection less influenced by such diminution. The presence of the active ERK in muscle nuclei is consistent with the role of ERK in the regulation of gene expression shown in other cell types.18,19 For example, under conditions of oxidative stress ERK, possibly in conjunction with other factors, induces transcription of c-fos and c-jun genes.10 ERK also increases phosphorylation and thereby activation of c-Fos and c-Jun proteins,18,19 which are components of the AP-1 transcription factor complex that induces expression of the AßPP gene.22 Because IBM abnormal muscle fibers have strongly increased AßPP mRNA,5 and increased expression of c-Jun and c-Fos proteins and Jun kinase (Broccolini and Askanas, unpublished observations, 1999), their increased ERK activity might participate in the AßPP gene induction and the c-Fos/c-Jun expression. Aß, an amyloidogenic fragment of AßPP that is also increased in IBM muscle fibers,4 itself can induce ERK activity in cultured cells.23,24 We therefore propose that in IBM increased AßPP and Aß lead to oxidative stress which subsequently induces active ERK; and as a result of its activation, ERK stimulates AP-1 transcription factor causing even more of AßPP to be produced, creating a self-perpetuating destructive mechanism. Therefore, in IBM muscle fibers, ERK activation may have at least two pathogenic actions, increasing both the phosphorylation of tau and the AßPP gene expression.
Our novel localization of active ERK postsynaptically at all studied
human NMJs and its virtually exact co-localization with
-BT binding
suggest that active ERK may participate in signal transduction of
nerve-muscle interaction. Our finding is harmonious with a previous
study of cultured animal muscle in which ERK was shown to mediate
transduction of a signal from the muscle plasmalemmal neuregulin
receptor to muscle nuclei that induces ACh receptor gene
activation.25
Our immunolocalizations of active ERK, both at the human normal NMJs and in IBM muscle fibers, are consistent with our hypothesis of a pathological junctionalization of nonjunctional regions of IBM muscle fibers.1 In the normal innervated mature muscle fibers, genes of the various junctional proteins (proteins accumulated in normal fibers only at postsynaptic junctional regions) are down-regulated in the nonjunctional nuclei located in the vast nonjunctional regions of the muscle fiber. However, in the nonjunctional regions of IBM muscle fibers, many of the junctional proteins, and the mRNAs of some of them, are pathologically accumulated.1 Accordingly, we hypothesized that those abnormal nonjunctional accumulations in IBM muscle fibers result from a pathological extrajunctional activation of a factor or factors responsible for the normally junction-specific gene expression. Active ERK seems to be a factor mediating junction-specific gene expression,25 and it is prominently present at the normal human NMJ (this study). Its prominent accumulation in nonjunctional regions of IBM abnormal muscle fibers (perhaps because of the oxidative stress, an occult virus, or other factors) suggests that its cytoplasmic activation there may participate in derepressing nonjunctional nuclei and subsequent topographically aberrant production of various junctional proteins.
| Conclusion |
|---|
|
|
|---|
| Acknowledgements |
|---|
| Footnotes |
|---|
Supported in part by grants from the National Institutes of Health (NS34103 and AG16768) and the Muscular Dystrophy Association (all to V. A.).
G. M. W. is a postdoctoral fellow in Dr. Askanas laboratory.
Accepted for publication March 16, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. M. Rosen, V. Veereshwarayya, C. E-H. Moussa, Q. Fu, M. S. Goldberg, M. G. Schlossmacher, J. Shen, and H. W. Querfurth Parkin Protects against Mitochondrial Toxins and beta-Amyloid Accumulation in Skeletal Muscle Cells J. Biol. Chem., May 5, 2006; 281(18): 12809 - 12816. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Lang, K. A. Esser, and E. E. Dupont-Versteegden Altered Activity of Signaling Pathways in Diaphragm and Tibialis Anterior Muscle of Dystrophic Mice Experimental Biology and Medicine, June 1, 2004; 229(6): 503 - 511. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. M. Harris, I. Tesseur, W. J. Brecht, Q. Xu, K. Mullendorff, S. Chang, T. Wyss-Coray, R. W. Mahley, and Y. Huang Astroglial Regulation of Apolipoprotein E Expression in Neuronal Cells: IMPLICATIONS FOR ALZHEIMER'S DISEASE J. Biol. Chem., January 30, 2004; 279(5): 3862 - 3868. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nakano, A. Shinde, H. Ito, H. Ito, and H. Kusaka MAP kinase phosphatase-1 is induced in abnormal fibers in inclusion body myositis Neurology, August 12, 2003; 61(3): 322 - 326. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |